Despite these findings, our studies also confirm that glucagon is an attractive metabolic disease therapeutic as it improves glycemia and hepatic steatosis in the context of dietary protein supplementation, an intervention that helps to prevent lean mass loss. This evidence concerns the gene GCG and metabolic disease.